WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
California's population grew in 2023, halting 3 years of decline
Google plans to invest $2 billion to build data center in northeast Indiana, officials say
Husband saw his wife, 50, die trying to save their beloved Labrador from a fast
New York to require internet providers to charge low
EDEN CONFIDENTIAL: Prince Harry's army friend JJ Chalmers urges Kate to talk about cancer
Flight attendant indicted in attempt to record teen girl in airplane bathroom
Shocking moment Las Vegas substitute teacher, 27, brawls with student 'who called him the n
Animal groups are urging tourists not to visit Wyoming after a man hit a wolf then took it to a bar
Democrats vow to protect Speaker Mike Johnson from being ousted from office
Braves 2B Ozzie Albies activated from injured list ahead of series versus Guardians